BIO Europe Autumn 2024

Discover more at BIO Europe

At BIO Europe we will be seeking discussions with:

Biopharma companies seeking support to improve probability of success in developing novel therapeutics.
Investors with an interest in investing in clinical stage AI businesses.
Diagnostics companies that are interested in partnering to advance novel diagnostics for complex chronic diseases.

Send a message to Rowan Gardner in the BIO Europe Partnering Platform or contact us to setup a meeting outside of the event.

Precision is the future of biopharma R&D & healthcare

Join us at BIO Europe to see how AI-led precision medicine is maximizing value and success throughout drug development and healthcare.

Discovery
De-risking target evaluation and selection with knowledge of causal genetic, mechanistic explanation of observed clinical phenotype, mechanistic prevalence, match to TPP and secondary indications.

Development
Improving probability of success through indication prioritisation and mechanistic patient stratification biomarkers to design clinical trials that are faster to readout and more likely to succeed.

Portfolio
Increasing revenue potential of existing assets, identifying label extension opportunities, and developing complementary diagnostics to support prescribing of product to the patients who are most likely to benefit.

Healthcare
Developing a pipeline of novel diagnostics that assess disease risk, the specific mechanisms underpinning disease, and recommend treatments that are consistent with the mechanisms of action present in the patient.